BK Virus Infection (BKV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

BK polyomavirus (BKV) belongs to the Polyomaviridae family of double-stranded DNA (dsDNA) viruses. BKV is a common childhood infection that rarely leads to severe clinical consequences, and over 80% of adults have antibodies against BKV. BKV remains latent after the primary infection in healthy individuals and does not cause significant morbidity. However, in some immunosuppressed individuals, such as those with HIV infection or who have undergone transplantation, BKV may reactivate and cause clinical complications. Among these patients, kidney transplant recipients (KTRs) are the most commonly affected, with a median of 19.5% developing BK viremia after transplantation. BKV enters the bloodstream through infected tonsillar tissue, infecting peripheral blood mononuclear cells and spreading to secondary sites of infection, such as the kidney. BKV DNA has been detected in leukocytes, lymph nodes, and the brain. The mechanisms underlying viral persistence and reactivation upon immunosuppression remain unclear. The major clinical manifestations of BKV infection are BKV-associated nephropathy (BKVAN) or ureteric stenosis in KTRs and hemorrhagic cystitis, mostly seen in hematopoietic stem cell transplant (HSCT) recipients. Other less common clinical manifestations of BKV infection include interstitial pneumonitis and meningoencephalitis. Donor BKV seropositivity and recipient BKV seronegativity increase the risk of developing BKVAN and graft rejection, with a tenfold higher risk of BK viremia in KTRs when the donor is seropositive, and the recipient is seronegative, compared to cases where both are seronegative. Currently, no antiviral medications have strong evidence of clinical efficacy against BKV.

Thelansis’s “BK Virus Infection (BKV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential BK Virus Infection (BKV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of BK Virus Infection (BKV) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

BK Virus Infection (BKV) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: BK Virus Infection (BKV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033